Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$11.7B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and the acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $12 billion, its work is significant in the healthcare sector as it addresses unmet medical needs in areas like depression and migraine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, missing estimates by 48%. Despite this, the stock rose 8.31% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating Axsome's upcoming earnings report with uncertainty, especially after mixed results in previous quarters.

Bull Case

If Axsome can demonstrate improved EPS and revenue growth, it could signal strong demand for its products and boost investor confidence.

Bear Case

Conversely, if the company continues to miss earnings expectations, it may raise concerns about its financial stability and product viability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for this quarter?

Given the company's history of missing EPS estimates, a significant improvement or continued decline will heavily influence market sentiment.

How is revenue expected to trend this quarter?

Revenue growth is critical for Axsome's future, and any signs of stagnation could lead to negative market reactions.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Axsome's products to gain traction in the market, especially given the recent uptick in interest in mental health treatments.

Supporting Evidence

The stock has shown resilience with an 8.31% increase despite a significant EPS miss last quarter.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

The company's focus on central nervous system disorders aligns with growing healthcare trends.

Key Risk

If Axsome's revenue shows unexpected growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery in earnings against the backdrop of previous misses.

Bull Confirmed If

An EPS improvement to -$0.80 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$1.50 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a positive reaction, with an average 1-day move of +2.93%, confirming investor confidence.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should the company miss again, history suggests a potential downside of around +1.28%, which could raise serious concerns about its trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on market demand for current therapies.
3Insights into competitive landscape changes.
4Management's outlook on future earnings and revenue.
5Responses to analyst questions regarding past performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and the acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, missing estimates by 48%. Despite this, the stock rose 8.31% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating Axsome's upcoming earnings report with uncertainty, especially after mixed results in previous quarters.

Bull Case

If Axsome can demonstrate improved EPS and revenue growth, it could signal strong demand for its products and boost investor confidence.

Bear Case

Conversely, if the company continues to miss earnings expectations, it may raise concerns about its financial stability and product viability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for this quarter?

Given the company's history of missing EPS estimates, a significant improvement or continued decline will heavily influence market sentiment.

How is revenue expected to trend this quarter?

Revenue growth is critical for Axsome's future, and any signs of stagnation could lead to negative market reactions.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Axsome's products to gain traction in the market, especially given the recent uptick in interest in mental health treatments.

Supporting Evidence

The stock has shown resilience with an 8.31% increase despite a significant EPS miss last quarter.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

The company's focus on central nervous system disorders aligns with growing healthcare trends.

Key Risk

If Axsome's revenue shows unexpected growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery in earnings against the backdrop of previous misses.

Bull Confirmed If

An EPS improvement to -$0.80 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$1.50 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a positive reaction, with an average 1-day move of +2.93%, confirming investor confidence.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should the company miss again, history suggests a potential downside of around +1.28%, which could raise serious concerns about its trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on market demand for current therapies.
3Insights into competitive landscape changes.
4Management's outlook on future earnings and revenue.
5Responses to analyst questions regarding past performance.